The aim of the present study was to assess the feasibility of a 3D tumor cell culture model, that is, multicellular tumor sphe roids (MCTSs) as an adequate model for micrometastases and therefore as a pharmacological model for efficacy testing of trifunctional therapeutic antibodies. Unlike conventional monolayer cultures, spheroids allow researchers to study parame ters, such as 3D cell shape, 3D cell arrangement and microenvironment, and penetration efficiency of defense cells that may largely influence the efficacy of antibody treatment in vivo. The authors established a longterm coculture of human MCTSs with peripheral blood mononuclear cells (PBMCs) to test the anticancer effect of the trifunctional, bispecific antibody catu maxomab (antiEpCAM × antiCD3) or similar therapeutic molecules. The test system is accessible to various analytical methods and thus allows for characterizing multiple parameters, which can help elucidate the mode of action of immuno therapeutic anticancer treatment. For example, the novel approach enables precise, reproducible volume growth analysis of MCTSs under immunotherapeutic treatments. For evaluation of changes within individual spheroids, cryosections can be stained (e.g., for proliferating or apoptotic cells as well as infiltrating PBMCs). Molecular PCRbased assays or flow cyto metric analyses allow for discrimination between different cell types, particularly leukocyte subtypes. Furthermore, MCTSs can be disaggregated to form standard monolayers for cell viability or plating efficiency experiments. For these reasons, the MCTS model is a powerful tool to analyze drug efficacy with various endpoints under highly reproducible, standardized conditions. (Journal of Biomolecular Screening 2009:980990) 
INTRODUCTION
R ecent articles emphasize the impact of 3D tumor cell culture in contrast to 2D monolayer culture on anticancer research. 1 Different multidimensional models have been des cribed in literature, including organotypic explant cultures, mul tilayer cultures, 3D cell cultures on artificial scaffolds, and multicellular tumor spheroids (MCTSs). 2 MCTSs are 3D cell aggregates that can be generated from routinely used cell lines. Tumor spheroids have a substantial similarity to avascular micrometastases or intervascular microregions of solid in situ tumors. They develop nutritional, metabolic, and oxygen gradi ents and show comparable growth kinetics with distinct differen tiated cell populations from proliferating to necrotic cells. 3 Because of their 3D, tissuelike architecture, the single tumor cell within an MCTS shows various differences compared to cells grown in standard monolayer cultures, which is true for cell shape, malignant behavior, 4 or energy metabolism 5 mostly due to altered gene expression. 6 Furthermore, spheroids feature a stronger comparability with solid tumors regarding cellcell and cell matrix interactions. Since the beginnings of MCTS culture and its use in radiation research in 1970, 7 many different groups used MCTS models for studies in various tumor biology fields such as invasion and metastasis, angiogenesis, cell cycle regulation, metabolism, and cell death or proliferation. In addition to radia tion biology, MCTSs were used for studies with chemo and immunotherapeutics (reviewed by MuellerKlieser 8, 9 ) . With regard to the latter field of research, the 3D model enables long term coculture with immune cells 10 to study tumorimmune cell interactions. We applied MCTS coculture for the evaluation of the therapeutic antibody catumaxomab for immune cellmediated antitumor effects.
Catumaxomab (TRION Pharma GmbH, Munich, Germany) is a bispecific, trifunctional monoclonal antibody consisting of mouse IgG2a and rat IgG2b. 11 The antibody has 3 different binding sites: the mouse Fab fragment binds to the human tumorassociated antigen EpCAM (epithelial cell adhesion molecule), the rat Fab fragment targets human CD3 on T cells, and a third functional binding site within the hybrid Fcregion selectively binds and activates Fcγreceptorpositive accessory cells. Because EpCAM expression is detected in many tumor tissues of different origin, the application of catumaxomab is indicated for diverse epithelial tumor entities. Catumaxomab has already been evaluated in clinical trials conducted by Fresenius Biotech GmbH (Munich, Germany); for malignant ascites, this is true for phase III trials, and for ovarian and gas tric cancer, it is in phase II testing. 1214 The mode of action of catumaxomab is based on the forma tion of a postulated tricell complex 15 consisting of tumor cells, T cells, and accessory immune cells such as macrophages, den dritic cells, or natural killer cells. The simultaneous recruitment and activation of T cells and accessory cells lead to costimula tion of T cells, improved tumor cell elimination by different killing mechanisms, and phagocytosis, as well as processing and presentation of tumor material by bound and activated accessory cells. This strategy offers an effective therapeutic tool under the exploitation of the natural immune defense. 16 To pro vide a better insight into the mode of action and effectiveness of catumaxomab in vitro, we applied our 3D tumor cell model.
MCTSs were generated from the human EpCAMpositive cell line FaDu (head and neck squamous cell carcinoma) and cocultured with peripheral blood mononuclear cells (PBMCs) under welldefined, standardized conditions in spinner flasks. This miniaturized rotating coculture partially imitates the sup ply with oxygen and nutrients of avascular sites of a tumor or micrometastasis in blood vessels, and hence our model displays a cellbased test system with strong relevance for the clinical in vivo situation.
METHODS

Generating and culturing of MCTSs
The human cell line FaDu (head and neck squamous cell carcinoma, HNSCC, donation of Michael Baumann, Technical University of Dresden, Germany) was grown in Dulbecco's modified Eagle's medium (DMEM) 4.5 g/L glucose (PAA, Pasching, Germany) supplemented with 2 mM Lglutamine (PAA), 10% fetal calf serum (FCS) gold (PAA), 1 mM sodium pyruvate (AppliChem, Darmstadt, Germany), 10 mM HEPES (Roth, Karlsruhe, Germany), 1% nonessential amino acids (PAA), and 1% Amphotericin B (PAA). Cells were cultured under standard tissue culture conditions and tested routinely for mycoplasma contaminations (MycoTest Venor, Minerva biolabs, Berlin, Germany). Because FaDu expresses EpCAM at a high level and generates MCTS with a nearly perfect round geomet ric shape, we used this cell line in the present study.
FaDu spheroid formation was initiated using the liquid over lay method 17 with adaption for 96well plates. 18 For this pur pose, the plates were coated with 1.5% agarose (Roth) 50 µL per well. Each well was filled with 1 × 10 4 tumor cells from exponential growth phase in 150 µL culture medium. After 2 to 4 days, the cultivated cells had formed 1 round aggregate in each well. After 1 week when the MCTSs reached a diameter of about 0.7 to 0.8 mm, they were transferred into spinner flasks with a total medium volume of 300 mL and 2100 to 2300 spheroids per flask. The spheroids were cultured for 1 more week on a magnetic induction plate with 130 rpm (VWR, Darmstadt, Germany) under standard conditions. On day 0 of the experiment, the spheroids were separated into equal popu lations with subsequent continuation of culturing in miniatur ized spinner flasks (Weathon, NJ) with a total culture volume of 20 mL and 200 spheroids per flask.
Generation of spheroid growth curves
With the beginning of the experiments, the mean diameter of the spheroid population in each spinner flask was determined every second day following a standardized protocol using a subpopulation of 10 spheroids per spinner flask: 2 orthogonal spheroid diameters were quantified using an inverted microscope equipped with an ocular micrometer. The respective data were used for generating spheroid volume growth curves. 3
Isolation of PBMCs
PBMCs were obtained from buffy coats (Transfusion Center, University of Mainz, Germany) of healthy donors. Leukocytes were separated by densitygradient centrifugation with LSM1077 (PAA). For this purpose, the buffy coat was diluted 1:4 with sterile phosphatebuffered saline (PBS), and 25 mL of this suspension was slowly poured over 25 mL separation medium. After a 20min centrifugation with 1200 g (Megafuge 1.0, Heraeus, Hanau, Germany) with breaks turned off, the interphase was transferred to a new reaction tube, washed twice with PBS, and centrifuged for 10 min with 300 g. The propor tion of granulocytes was less than 5%, controlled periodically by 0.03% methylene blue staining of blood smears. Cell num bers were determined in a Neubauer chamber after lysis of erythrocytes by 5min incubation with 1% acetic acid. The required amount of suspended leukocytes for a concentration of 1 × 10 6 /mL was directly given into the spinner flasks contain ing spheroids in culture medium.
Treatment with catumaxomab
Catumaxomab, which was produced using the quadroma technology, 19 was kindly supplied by TRION Pharma (Munich, Germany). The concentration used in the experiments was 2.5 ng/mL catumaxomab according to a total quantity of 50 ng per spinner flask. The antibody was added to the cultures once at day 0 of the experiments.
Immunohistochemistry
Incipient with day 1 of the coculture, every second day sphe roids were harvested from the spinner flasks and cryofixed in liquid nitrogen. Frozen spheroids were embedded in TissueTek  (Sakura, Torrance, CA) and serially cryosectioned (10 µm) with a microtome (Slee, Mainz, Germany). After overnight drying at room temperature, the sections were fixed with ace tone for 5 min at -20 °C. For antiCD45 (Dianova, Hamburg, Germany) and for antiKi67 (Dako, Hamburg, Germany), stainings with monoclonal antihuman mouse IgG1 antibodies were used. For antiKi67 staining, a preceding permeabiliza tion of the cell membranes with a permeabilizing buffer (PBS + 0.1% [v/v] TritonX100 + 0.1% [w/v] sodium citrate) was required. For secondary detection, antimouse EnVision and DAB + (Dako) were used according to the manufacturer's instruction. All sections were counterstained with hematoxylin (Roth). Sections were registered photographically using a light microscope (Axiophot, Zeiss, Oberkochen, Germany) and a digital camera (D100; Nikon, Tokyo, Japan). For quantitative analysis, median sections were selected and further processed by computerized analysis.
Apoptosis staining
Apoptosis was detected in paraformaldehydefixed cryosec tions using the FragEL DNA fragmentation detection kit (CalbiochemNovabiochem Ltd, Nottingham, UK). The princi ple of the test is based on end labeling of free 3′OH groups generated by endonucleases released during apoptosis. Nuclei were counterstained with mounting medium containing DAPI fluorescent dye as provided with the kit.
Quantification of penetrated leukocytes
Spheroid sections were analyzed with a transmitted light microscope, and photos were taken with a Nikon (D100) cam era. For quantification of infiltrated CD45 + cells, we con structed a template of concentric rings with Adobe Photoshop 6.0 in the same pixel size as the microphotographs. Appropriate magnifications and scale bars allow for calibrating the distance between 2 rings, which was 25 µm at a magnification of 10× and 50 µm at 5×, respectively. Centers of the image and the template were overlaid in Adobe Photoshop 6.0. With a further feature, it is possible to highlight single rings for an easier manual counting of the total amount of all spheroid cells and CD45 + , proliferating, and apoptotic cells. Counted cell num bers of each ring were normalized to the area of the individual ring (mm 2 ).
Cytokine quantification
Cellfree media supernatants of spheroid cultures were col lected every second day. Then, 200 µL were transferred into 1.5mL reaction tubes. Remaining solid particles were sedi mented by centrifugation for 10 min with 400 g at 4 °C. The supernatants were stored at -80 °C until the samples were analyzed with cytokine bead arrays (CBA, Th1/Th2 Cytokine Kit II, BD, Heidelberg, Germany). This flow cytometric tech nique allows for the quantification of interleukin2 (IL2), IL4, IL6, IL10, interferon gamma (IFNγ), and tumor necrosis fac tor alpha (TNFα).
RT-PCR
Spheroids were treated with or without 2.5 ng/mL catumax omab and PBMC. After 5 days of coculture, spheroids were washed 5 times in PBS to remove any attached PBMC. A posi tive control was generated by incubating PBMC with concana valin A (1 µg/mL) for 3 days.
Total RNA was extracted using the RNeasy Mini Kit, and a DNase digest was performed (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. Afterwards, RNA concentration was determined, and integrity was proofed by formaldehyde gel. Then, 200 ng of total RNA was reverse tran scribed using ReverseiT RTase Blend (Abgene, Hamburg, Germany) and Anchored Oligo dT primer (Abgene). Concentration of cDNA was determined, and 200 ng were used for CD4 PCR. Human CD4 was specifically amplified over 40 cycles by using FIG. 1. Spheroid volume growth curves as a standard endpoint mea surement. Experiments started at a FaDu spheroid diameter of approx imately 0.9 mm, which reflects a spheroid volume of 0.4 mm 3 . Volume growth kinetics under control conditions followed a Gompertz func tion, which is known to describe tumor growth in vivo. Dotted lines indicate mean values of 3 different donors. Controls (black squares) continued to grow up to 8 days of culture and then slightly decreased their volume but stayed over the size of day 0. Cocultured spheroids with peripheral blood mononuclear cells (PBMCs) of 3 different donors (circles) grew up to day 5 and maintained their volume of day 0. With PBMCs and 2.5 ng/mL catumaxomab, treated spheroids (tri angles) showed a continuous volume decrease after 3 days, which led to complete decomposition on day 11 (n = 200, standard deviations are shown as +SD or -SD where graphically appropriate). primers with sense 5′TCCTTCCCACTCGCCTTTACAG3′ and antisense 5′TCTCATCACCACCAGGTTCAC3′ with an annealing temperature of 66 °C. Products of 291 bp were ana lyzed on 1.2% agarose gels, and intensities were quantified by densitometric analysis (ImageJ, National Institute of Health, Bethesda, MD).
Flow cytometry
FaDu spheroids were either treated with 0.5 ng/mL catu maxomab and PBMC or with PBMC without catumaxomab (control) for 7 days. After mechanical separation, cells were incubated with mouse antihuman CD45 FACS antibody (BD) for 30 min and then fixed in paraformaldehyde. FACS Calibur (BD) was used to determine positively stained cells for CD45 and propidium iodide.
Clonogenic survival
For analysis of clonogenic survival and viability, sphe roids were disaggregated by trypsinization following a standard protocol to obtain a single cell suspension. Plating efficiency (PE) was used to determine the clonogenic sur vival. Cells were seeded with a density of 50 cells per cm 2 into 6well plates. After 6 doubling times (8 days for FaDu), cells were stained with 0.03% methylene blue. All colonies with a minimum of 50 cells were counted. PE was defined as PE (%) = (number of colonies observed/number of cells seeded) × 100.
Viability test
The XTT assay (Tox2, Sigma, Steinheim, Germany) was used to measure cell viability based on the activity of mito chondrial enzymes in live cells. Because viable cells are able to metabolize the tetrazolium salt XTT by mitochondrial dehydro genases into an orange formazan compound, the intensity of the colored product can be analyzed by photometry. For the XTT assay, cells were seeded with a density of 5 × 10 4 cells per well in 96well plates. After adherence of the cells overnight, medium was replaced by DMEM without phenol red and with out supplements. After 4 h of incubation with 20% XTT solu tion, absorbance was measured at 450 nm and 655 nm. The difference between E 450 and E 655 was calculated, and the result ing value was registered compared to the respective absorbance difference of the control cells (100%).
Statistics. Average values from multiple determinations are given as arithmetic mean values ± standard deviation (mean ± SD). Spheroid volume growth curves under control conditions were obtained by fitting the Gompertz function 20 to the mean spheroid volumes as a function of time in culture.
RESULTS
Spheroid volume growth curves
Decrease of spheroid volume growth is one of the most crucial endpoints in evaluation of therapy efficiency in the MCTS model system. For this reason, spheroid size was routinely determined. Culturing in the 96well plates before transferring MCTS into spinner flask led to uniform spheroid growth with a coefficient of variation of less than 5%. This was a necessary requirement for a continuing size measurement and determina tion of growthpromoting or growthsuppressing effects of treatments. Figure 1 shows the volume growth curve of FaDu spheroids incubated with 1 × 10 6 PBMC/mL and 2.5 ng/mL catumax omab. Spheroids under the combined treatment of antibody and PBMC continuously shrank over the entire observation period, whereas spheroid volume growth entered a plateau phase under control conditions. After 11 days, catumaxomabtreated spheroids in cocultures were completely disintegrated into single cells and debris. The coefficient of variation between the curves of the 3 PBMC donors was less than 11%; for combined treat ment, it was less than 20%.
There was a difference of up to 35% on day 9 between the diameters of control spheroids without PBMC compared to those with PMBC throughout all experiments, implying minor allogenic effects within these spheroid cocultures.
Plating efficiency
Beside spheroid size as an endpoint of drug treatment, moni toring the ability of single cells of forming colonies was quanti fied. Relative survival was determined as the ratio of the PE of treated cells to that of untreated controls. Untreated FaDu cells
FIG. 3. Immunohistochemical staining of CD45positive cells penetrated into FaDu spheroids. FaDu tumor cell spheroids + peripheral blood mononuclear cells (PBMCs) alone (upper panel) and spheroids incubated with 2.5 ng/mL catumaxomab + PBMC (lower panel)
were stained for antiCD45 (brown) and counterstained with hematoxylin (blue). On day 3, spheroids had nearly an equal size of 0.85 mm, but catumaxomab treatment was already associated with a massive infiltration of CD45+ cells. After 2 more days of coculture, control spheroids increased in size and still showed only sparely distributed CD45 + cells, whereas tumor spheroids incubated with the antibody diminished in diameter and showed a massive increase of invading immune cells. These effects were even more distinct on day 10. In addition, development and disappearance of the necrosis can be observed in the sections.
showed a PE of about 20% independent of the cell number seeded. Combined treatment with PBMC and 2.5 ng/mL catumaxomab reduced the ability of the cells to form colonies by around 98% after 6 days of therapy compared to control ( Fig. 2a) .
XTT viability assay
In an XTT assay, single tumor cells from disaggregated spheroids with combined treatment of PBMC and 2.5 ng/mL FIG. 4. Apoptosis and proliferation staining of control and dualtreated FaDu spheroids. On day 6, spheroids of coculture with peripheral blood mononuclear cells (PBMCs) and spheroids following combined treatment with PBMCs and 2.5 ng/mL catumaxomab were stained for apoptosis (green). Apoptotic cells were preferentially localized in the center of the control spheroids, whereas antibodytreated coculture spheroids showed a more even distribution of apoptosis over the entire spheroid. Nuclei were stained with DAPI (blue). Once again, a difference in spheroid size between treated and untreated spheroids was observed. Proliferating cells were stained for Ki67 (brown) and counterstained with hematoxylin (blue). Proliferating cells reside in the outer viable rim of the control spheroids treated with PBMCs alone as well as of spheroids treated with 2.5 ng/mL catumaxomab and PBMC, whereas in the dualtreated spheroids, the number of Ki67 + was strongly decreased. catumaxomab showed only 10% metabolically active cells compared to control conditions (Fig. 2b) . Similar to the PE assays ( Fig. 2a) , the tumor cells in coculture with PBMC were already affected by the presence of immune cells alone. This was reflected by 46% reduction in clonogenicity (colony forming assay) and 27% decrease in viability (XTT assay) of tumor cells after incubation with PBMC without antibody com pared to control conditions. The reduced viability of spheroid cells treated with PBMC and catumaxomab provides further evidence for an efficient antitumor effect caused by the anti body therapy.
Immunohistochemical stainings
Serial 10µmthick acetonefixed cryosections of the whole spheroid allow for the determination of the equatorial or central section, which is identified as the largest section within the series. All histological evaluations with regard to the spatial distribution of cells and molecules within sphe roids are based on such equatorial or adjacent sections. These were stained with αCD45 and αKi67 antibodies.
In coculture with PBMC, we determined infiltration of MCTS by CD45 + cells. Figure 3 shows the comparison of MCTS cryosections of cocultured spheroids or combined treat ment with 2.5 ng/mL catumaxomab, respectively. There were 2 striking observations: first, it is apparent that the size of both approaches developed in opposite ways; although control spheroids increased their size during the observation period of 10 days, the combined treatment (consisting of catumaxomab + PBMC) induced a dramatic shrinkage. Second, control spher oids contained only a few CD45 + cells; in contrast, antibody treated spheroids exhibited a massive leukocyte infiltration. In the initial phase of the experiment, the CD45+ cells were located at the spheroid perimeter. With increasing time, these cells penetrated deeper into the spheroids.
Apoptosis and proliferation
Growth inhibition of spheroids can be caused by either decreased proliferation or increased cell death. Possible mecha nisms are the development and expansion of the central (preexisting) necrosis, as well as initiation of apoptosis of tumor cells by infiltrating leukocytes. Therefore, we analyzed apoptosis on median cryosections with FragEL staining. Representative stainings are shown in Figure 4 . Green cells indicate apoptotic cells, which were preferentially located in areas near the central necrosis in untreated spheroids (Fig. 4, upper panel) and were more evenly distributed over the viable rim in spheroids follow ing combined treatment (2.5 ng/mL catumaxomab + PBMC of 3 different donors). Proliferating cells were visualized via antiKi67 staining (Fig. 4, lower panel) , which marks proliferat ing cells. Positive stainings were found predominantly in the outer viable rim of the spheroids in both control and treated spheroids, whereas the proportion of proliferating cells was decreased in the MCTS with catumaxomab and PBMC.
Cytokines in culture supernatants
Concentrations of various cytokines were measured over the entire observation period. Figure 5 shows representative results for various cytokines in cellfree coculture supernatants of spheroids treated with 2.5 ng/mL catumaxomab and PBMC in comparison to the controls. The obtained concentration pat terns of IFNγ and IL6 in spheroids cocultured with PBMC and catumaxomab are typical of that of an acute inflammatory reaction, which is typically observed with immunotherapy.
FACS analysis
FACS analysis of spheroids that were treated for 7 days with 0.5 ng/mL catumaxomab and PBMC was accomplished for CD45positive cells (data not shown). The results correlated with findings of the immunohistochemical antiCD45 stain ings. In total, there were an average number of 1.300 cells per median spheroid section from which about 50 cells were CD45 + (i.e., a proportion of 3.9%).
Quantification of different cell-type penetration
After cryoconservation and serial sectioning, slices were stained with antiCD45, antiKi67, and FragEL. Our established method of quantification by overlaying a spheroid picture with FIG. 5. Culture supernatants of day 5 were analyzed for various cytokines. FaDu spheroid cultures (white) showed nearly nondetect able levels of the analyzed cytokines, except for interleukin6 (IL6). Supernatants from cocultures contained all analyzed cytokines, par ticularly very high levels of interferon gamma (IFNγ) and IL6. Concentrations in coculture with 2.5 ng/mL catumaxomab (black) were 400fold for IFNγ, and for IL10 and tumor necrosis factor alpha (TNFα), they were about 2fold higher than in coculture without antibody (gray). a template of concentric rings (Fig. 6a ) enabled us to cross correlate results obtained in different parallel sections stained for different antigens. Figure 6b shows the results of FaDu spheroids treated with 2.5 ng/mL catumaxomab for 6 days. Apoptotic cells were located in the center of the spheroid; in the central zone of the viable rim, quiescent tumor cells, leukocytes, and some proliferating cells could be found. Most of the prolif erating cells were detectable in the outermost layer of the viable rim. The quantification histogram (Fig. 6b ) not only summarizes the number of different cell types; moreover, it provides informa tion about their localization and distribution within the spheroid.
RT-PCR analysis
Spheroids were cocultured with PBMC and treated with 2.5 ng/mL catumaxomab for 5 days. The CD4+ portion of infiltrated leukocytes was analyzed by amplification of CD4 transcripts by RTPCR. In accordance with the histological stain ings, the CD4 signal in the samples treated with the antibody was more intensive than in controls (Fig. 7) . This finding confirmed that catumaxomab therapy leads to a longterm activation of PBMC and redirects them to the tumor cells.
DISCUSSION
In this study, MCTSs have been shown to be suitable for rou tine preclinical testing in anticancer immunotherapy. They reflect pathophysiological characteristics, complexity, and heterogeneity of tumor tissue in vivo that critically affect therapeutic efficacy. Our established method of cocultivating MCTS with PBMC and FIG. 6. Method of quantifying cell penetration in spheroids. (a) Quantification of various stained cell types was processed by overlaying spher oid sections with a template of concentric rings with a defined ringtoring distance. As an example, a FaDu spheroid + 2.5 ng/mL catumaxomab + peripheral blood mononuclear cells (PBMCs) on day 6 stained for CD45 is shown. Cell numbers were counted in each ring, and the relative cell number per square millimeter was calculated. (b) Data obtained from quantification of antiCD45 (white), FragEL (black), antiKi67 (light grey), and only nucleistained (dark gray) cells were summarized in a distribution histogram. Results show that treatment with 2.5 ng/mL catu maxomab for 6 days caused an infiltration of leukocytes even into the spheroid center. Apoptotic cells were equally distributed over the whole section. Most of the proliferating cells were found at a radial distance of 75 µm from the surface. the spheroid diameters and generate volume growth curves. Furthermore, spheroids can be sectioned and stained for PBMC infiltration as well as for analysis of apoptosis and proliferation. Beyond the analysis of the spheroids, the culture supernatant serves as an indicator for cytokine activity of PBMCs in our the trifunctional antibody catumaxomab in miniaturized rotating suspension cultures allow for longterm cultivation and provide various endpoints of investigation (summarized in Fig. 8) .
The system offers the possibility to use the spheroid model in 3 different ways: the intact MCTSs can be used to measure FIG. 8. Scheme of lately established pharmacological model: spheroid generation starts with seeding cells in 96well plates for spontaneous cell aggregation. After 1 week of culture, the spheroids are transferred into a large spinner flask for 1 more week. Then they are separated into miniaturized flasks, and the experiments start by addition of freshly isolated peripheral blood mononuclear cells (PBMC) and the trifunctional antibody catumaxomab. This point of time was defined as day 0. During the following days, spheroids can be removed and either cryofixed or disaggregated for further assays. Supernatant samples can be collected and analyzed. This system is stable for up to 2 weeks and only limited by the spheroid sizedecreasing effects of the investigated drug.
rotating culture system. Our results show that the immune cells are viable and in an activated state during culturing in the spin ner flasks over the experimental period of about 2 weeks. Noticeable data are the high levels of IL6 in the coculture, especially with regard to accumulating literature identifying a link between IL6 secretion, inflammatory status, and malig nancy of tumors. 2123 In addition to spheroid and cytokine studies, the system provides the possibility of using all common biomolecular methods after disaggregation of the spheroids into a single cell suspension. We applied the system for viability assay, plating efficiency, FACS analysis, and PCR. Clonogenicity is a crucial parameter for the recurrence and metastatic potential of tumor cells. On the basis of immunohistology and molecular biology, we detected the infiltration of CD45 + leukocytes into the antibodytreated spheroids. Different recent articles emphasize the relevance of immune cell invasion in tumors of different entities for the survival of patients. 2430 For this reason, the antibodymediated redirection of immune cells and their pene tration into the spheroids seem to develop as a major mecha nism involved in antitumor efficiency. Because of the importance of leukocyte invasion, we established an easy method-in con trast to other published procedures 31 -to quantify the PBMC infiltration into the MCTS. The method offers the possibility to generate histograms that reflect the number and depth of pen etrated immune cells. With the ability to quantify specifically stained cell types easily, these immunohistological stainings gain further relevance for immunological investigations.
There are several different techniques to generate spheroids: agarosecoated Petri culture dishes can be used in which cells form spheroids of various sizes followed by separating different sizes of interest by sedimentation within a pipette. Other tech niques include the preparation of spheroids from hanging drops 32, 33 on the top of culture dishes or the use of roller tubes, gyratory shakers, or rotating wall vessels, which is the earliest develop ment. 34, 35 The essential advantage of our system is the possibility of producing spheroids of almost identical size in a reproducible way; also, it provides an optimum of nutrient supply and oxygen diffusion by the use of rotating spinner flasks. An argument against spinner flasks would be the need of large amounts of culture medium and respective high amounts of test substances. But even this argument is devastated by utilization of miniatur ized spinner flasks with a culture volume of only 20 mL, which is comparable to volumes used in monolayer culture flasks.
The use of MCTS as a standard test system in high throughput screening was already discussed 36 but was restricted to a stationary multititer format. To improve the rotating MCTS model in spinner flasks as a routine technique in drug testing, an easy and rapid handling of culturing and analyses is required. With our selection of endpoints and analytical methods, we standardized the evaluation of drug efficacy for our system. Nevertheless, there is still a lack of further automated analyti cal tools for standardized endpoints. Further investigations will be focused on the development of computerized quantification for generating strongly objective results. Furthermore, we will center on identifying the proportions and relevance of different immune cell subtypes that infiltrate into the spheroids. It will increase the understanding of the mode of action of spheroid shrinkage and, along with this, the therapeutic potency. But so far, our established in vitro minitumor model is usable for sta ble, reproducible, longterm analysis of 3D cocultures and is much closer to the in vivo situation than monolayer cultures or stagnant spheroid cultures (e.g., in microplates). Our model is adaptable to a multitude of pharmacological studies just by assignment of the cell line with the corresponding entity or target antigen on the surface. About 60% to 70% of all common cell lines are able to generate spheroids. A list of cell lines forming MCTS, at least in microplates, was published recently. 34 With all striking advantages of 3D tumor cell cultivation, it will gain stronger relevance for future antitumor drug testing.
